Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sampei, Zenjiro ^a   Igawa, Tomoyuki ^a   Soeda, Tetsuhiro ^a   Okuyama Nishida, Yukiko ^a   Moriyama, Chifumi ^a   Wakabayashi, Tetsuya ^a   Tanaka, Eriko ^a   Muto, Atsushi ^a   Kojima, Tetsuo ^a   Kitazawa, Takehisa ^a   Yoshihashi, Kazutaka ^a   Harada, Aya ^a   Funaki, Miho ^a   Haraya, Kenta ^a   Tachibana, Tatsuhiko ^a   Suzuki, Sachiyo ^a   Esaki, Keiko ^a   Nabuchi, Yoshiaki ^a   Hattori, Kunihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 910; BLOOD CLOTTING FACTOR 8; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PURIFICATION; DRUG RESEARCH; HAPLORHINI; ION EXCHANGE CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION;

ANTIBODIES, BISPECIFIC; EPITOPES; FACTOR VIII; HUMANS; IMMUNOGLOBULIN G; ISOELECTRIC POINT; SOLUBILITY; T-LYMPHOCYTES;

EID: 84874562364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057479     Document Type: Article

References (48)

1. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, et al. (2006) Practice patterns in haemophilia A therapy- global progress towards optimal care. Haemophilia 12: 75-81.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535-544.
3. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, et al. (2012) Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 18: 63-68.
4. Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, et al. (2012) Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 119: 612-618.
5. Shi Q, Kuether EL, Schroeder JA, Fahs SA, Montgomery RR, (2012) Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice. Haemophilia 18: 639-646.
6. Berntorp E, Shapiro AD, (2012) Modern haemophilia care. Lancet 379: 1447-1456.
7. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109: 546-551.
8. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, et al. (2011) Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 365: 1684-1692.
9. Chan AC, Carter PJ, (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301-316.
10. Weiner LM, Surana R, Wang S, (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
11. Beck A, Wurch T, Bailly C, Corvaia N, (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352.
12. Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, et al. (2007) A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 110: 2408-2413.
13. Mayorov AV, Amara N, Chang JY, Moss JA, Hixon MS, et al. (2008) Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. Proc Natl Acad Sci U S A 105: 17487-17492.
14. Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Kuan HF, et al. (2012) A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61: 1263-1271.
15. Songsivilai S, Lachmann PJ, (1990) Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol 79: 315-321.
16. Baeuerle PA, Kufer P, Bargou R, (2009) BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11: 22-30.
17. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, et al. (2010) Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 285: 20850-20859.
18. Fay PJ, Haidaris PJ, Smudzin TM, (1991) Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 266: 8957-8962.
19. Fay PJ, Koshibu K, (1998) The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 273: 19049-19054.
20. Lapan KA, Fay PJ, (1997) Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 272: 2082-2088.
21. Lapan KA, Fay PJ, (1998) Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost 80: 418-422.
22. Lenting PJ, Donath MJ, van Mourik JA, Mertens K, (1994) Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269: 7150-7155.
23. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, et al. (2012) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18: 1570-1574.
24. Kontermann R, (2012) Dual targeting strategies with bispecific antibodies. MAbs 4: 182-197.
25. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, et al. (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 4: 653-663.
26. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, et al. (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16: 677-681.
27. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, et al. (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3: 243-252.
28. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G, (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525.
29. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, et al. (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23: 385-392.
30. Mason BD, Zhang L, Remmele RL Jr, Zhang J, (2011) Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci 100: 4587-4596.
31. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, et al. (2009) Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 392: 145-154.
32. Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I, (2007) Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7: 405-418.
33. De Groot AS, McMurry J, Moise L, (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8: 620-626.
34. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, et al. (2009) T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev 61: 965-976.
35. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, et al. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33: 4-15.
36. Shima M, Matsumoto T, Ogiwara K, (2008) New assays for monitoring haemophilia treatment. Haemophilia 14Suppl 3: 83-92.
37. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, et al. (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20: 597-601.
38. Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, et al. (1999) A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 180: 35-40.
39. Lacy SE, DeVries PJ, Xie N, Fung E, Lesniewski RR, et al. (2008) The potency of erythropoietin-mimic antibodies correlates inversely with affinity. J Immunol 181: 1282-1287.
40. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, et al. (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371-378.
41. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, et al. (2000) Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 292: 810-816.
42. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, et al. (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3: 61-66.
43. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW, (2012) Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 3: 73-92.
44. Richter WF, Bhansali SG, Morris ME, (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14: 559-570.
45. Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP, (2012) Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia 18: e241-246.
46. Shire SJ, Shahrokh Z, Liu J, (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402.
47. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, et al. (2010) Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 19: 954-966.
48. Okuda M, Yamamoto Y, (2004) Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol 26: 215-223.